Pipeline

Indication
Asset
Preclinical
Phase I
Phase 2A
Phase 2B
Phase 3
Treatment Resistant Depression
MIND001
Treatment Resistant Depression - MIND001
Migraine Prevention
MIND002
Migraine Prevention - MIND002
Cluster Headache Prevention
MIND002
Cluster Headache Prevention - MIND002

MIND001

Intravenous formulation of N,N-Dimethyltryptamine to treat - Treatment Resistant Depression.

MIND002

Oral Psilocybin formulation to treat headache disorders - Migraine and Cluster Headaches.

With N = 36 completed and N > 100 in progress, early data show promising differentiation across safety, efficacy, dosing, and monitoring. Reduced psychedelic trip burden, minimal monitoring, and no psychotherapy requirement support a highly scalable care model vs existing treatment options.